Description
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include, NGM313 (MK-3655), NGM120, NGM621, and NGM395 among others. These are focused on NASH, diabetes, oncology, AMD and metabolic disease.